Axa
EXAS

Axa’s Exact Sciences EXAS Stock Holding History

Axa’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,767
Closed -$1.3M – 79
2025
Q4 		$1.3M Sell
12,767
-2,195
-15% -$176K 0.61% 34
2025
Q3 		$819K Sell
14,962
-559,181
-97% -$27.9M 0.41% 51
2025
Q2 		$30.5M Buy
574,143
+17,493
+3% +$889K 0.09% 202
2025
Q1 		$24.1M Sell
556,650
-39,571
-7% -$2M 0.08% 239
2024
Q4 		$33.5M Sell
596,221
-19,721
-3% -$1.23M 0.1% 197
2024
Q3 		$42M Buy
615,942
+990
+0.2% +$55.9K 0.12% 169
2024
Q2 		$26M Buy
614,952
+138,442
+29% +$7.62M 0.08% 232
2024
Q1 		$32.9M Sell
476,510
-7,659
-2% -$484K 0.1% 206
2023
Q4 		$35.8M Buy
484,169
+29,244
+6% +$1.92M 0.12% 187
2023
Q3 		$31M Buy
454,925
+192
+0% +$16.3K 0.11% 193
2023
Q2 		$42.7M Sell
454,733
-151,473
-25% -$11.8M 0.14% 164
2023
Q1 		$41.1M Buy
606,206
+21,629
+4% +$1.39M 0.14% 172
2022
Q4 		$28.9M Buy
584,577
+41,512
+8% +$1.7M 0.1% 232
2022
Q3 		$17.6M Buy
543,065
+30,486
+6% +$1.26M 0.07% 304
2022
Q2 		$20.2M Sell
512,579
-8,399
-2% -$449K 0.07% 295
2022
Q1 		$36.4M Sell
520,978
-52,401
-9% -$3.83M 0.1% 230
2021
Q4 		$44.6M Buy
573,379
+62,398
+12% +$5.51M 0.11% 209
2021
Q3 		$48.8M Buy
510,981
+202,313
+66% +$21.4M 0.14% 185
2021
Q2 		$38.4M Buy
308,668
+81,191
+36% +$9.69M 0.11% 215
2021
Q1 		$30M Buy
227,477
+30,310
+15% +$4.15M 0.09% 259
2020
Q4 		$26.1M Sell
197,167
-49,744
-20% -$6.02M 0.08% 272
2020
Q3 		$25.2M Buy
246,911
+65,639
+36% +$5.67M 0.09% 251
2020
Q2 		$15.8M Buy
181,272
+47,454
+35% +$3.79M 0.06% 328
2020
Q1 		$7.76M Buy
133,818
+62,030
+86% +$5.04M 0.04% 419
2019
Q4 		$6.64M Sell
71,788
-1,119
-2% -$98.4K 0.03% 549
2019
Q3 		$6.59M Buy
72,907
+16,198
+29% +$1.85M 0.03% 564
2019
Q2 		$6.69M Sell
56,709
-3,191
-5% -$322K 0.03% 570
2019
Q1 		$5.19M Sell
59,900
-26,500
-31% -$2.26M 0.02% 636
2018
Q4 		$5.45M Sell
86,400
-12,000
-12% -$824K 0.02% 580
2018
Q3 		$7.77M Buy
98,400
+75,642
+332% +$4.93M 0.03% 545
2018
Q2 		$1.36M Sell
22,758
-128,400
-85% -$6.91M 0.01% 936
2018
Q1 		$6.1M Buy
151,158
+19,658
+15% +$959K 0.02% 595
2017
Q4 		$6.91M Buy
131,500
+73,100
+125% +$3.9M 0.03% 576
2017
Q3 		$2.75M Sell
58,400
-2,700
-4% -$109K 0.01% 763
2017
Q2 		$2.16M Buy
61,100
+18,800
+44% +$580K 0.01% 770
2017
Q1 		$999K Buy
42,300
+4,600
+12% +$91.2K ﹤0.01% 931
2016
Q4 		$504K Buy
+37,700
New +$609K ﹤0.01% 1047

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Axa's EXAS Position: Q1 2026 in Review

Axa sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 12,767 shares — an estimated $1.3M sold.

Axa first reported a position in EXAS in Q4 2016 and held it in 37 quarters. The position peaked at $48.8M in Q3 2021. 6 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Axa reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Axa sold 12,767 Exact Sciences shares in Q1 2026, an estimated $1.3M.
  • Axa first reported a position in Exact Sciences in Q4 2016 and held it in 37 quarters.
  • Axa's Exact Sciences position peaked at $48.8M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Axa's 13F filing for Q1 2026, filed 15 May 2026.